Cyclophosphamide is clinically useful in treating malignancy and rheumatologic disease, but has limitations in that it induces hyponatremia. The mechanisms by which cyclophosphamide induces water retention in the kidney have yet to be identified. This study was undertaken to test the hypothesis that cyclophosphamide may produce water retention via the proximal nephron, where aquaporin-1 (AQP1) and aquaporin-7 (AQP7) water channels participate in water absorption. To test this hypothesis, we gave a single dose of intraperitoneal cyclophosphamide to male Sprague-Dawley rats and treated rabbit proximal tubule cells (PTCs) with 4-hydroperoxycyclophosphamide (4-HC), an active metabolite of cyclophosphamide. In the short-term 3-day rat study, AQP1 protein expression was significantly increased in the whole kidney homogenates by cyclophosphamide administration at 48 (614 ± 194%, P < 0.005), and 96 (460 ± 46%, P < 0.05) mg/kg BW compared with vehicle-treated controls. Plasma sodium concentration was significantly decreased (143 ± 1 vs. 146 ± 1 mEq/ L, P < 0.05) by cyclophosphamide 100 mg/kg BW in the long-term 6-day rat study. When primary cultured rabbit PTCs were treated with 4-HC for 24 hours, the protein expressions of AQP1 and AQP7 were increased in a dose-dependent manner. Quantitative polymerase chain reaction revealed no significant changes in the mRNA levels of AQP1 and AQP7 from cyclophosphamide-treated rat renal cortices. From these preliminary data, we conclude that the proximal nephron may be involved in cyclophosphamide-induced water retention via AQP1 and AQP7 water channels. Further studies are required to demonstrate intracellular mechanisms that affect the expression of AQP proteins.
Introduction
Some pharmacologic agents have been shown to have water-retaining properties. Whereas the antidiuretic actions are used to advantage in the treatment of patients with diabetes insipidus, there have been numerous reports disease. It can produce an antidiuretic effect when injected intravenouisly into water-loaded patients 2, 3) . We recently reported that cyclophosphamide-induced hyponatremia is not rare even when low-dose pulse cyclophosphamide is used 4) . However, the mechanisms by which cyclophosphamide induces water retention in the kidney have not been defined.
The main water channels participating in water conservation along the renal tubule are aquaporin-1 (AQP1) and aquaporin-2 (AQP2). AQP1 is abundant in the apical and basolateral membranes of renal proximal tubules and descending thin limbs. AQP2 is localized in the apical membrane and in intracellular vesicles which are targeted to the apical plasma membranes when stimulated by vasopressin 5) . The traditional view was that some drugs including cyclophosphamide may potentiate the action of vasopressin on the kidney, but this explanation has never been verified in cases with cyclophosphamide-induced water retention.
In this study, we hypothesized that in producing water retention in the proximal tubule and Henle's thin descending limb, the AQP1 water channel may have a role in cyclophosphamide-induced hyponatremia. To test this hypothesis, the expression of AQP1 was investigated both in vivo and in vitro after the administration of cyclophosphamide and its active metabolite 4-hydroperoxycyclophosphamide (4-HC), respectively. . Serum and urine samples were collected at the time each rat was killed for determination of electrolytes and osmolality. The experimental protocols were approved by the institutional Animal Care and Use Committee of Hanyang University.
Materials and Methods

Animal experiments of cyclophosphamide administration
Proximal tubular cell culture and treatment with 4-HC
Primary cultured renal proximal tubular cells (PTCs)
of New Zealand White male rabbits (1.5-2.0 kg) from Dae Han Experimental Animal (Chungju, Korea) were prepared as previously described 7) . . These concentrations were previously selected to imitate relevant serum levels of 4-HC in patients receiving moderate-to high-dose cyclophosphamide therapy [10] [11] [12] . Cells were harvested in 1 to 3 days after the 4-HC treatment for immunoblot analysis.
Preparation of cytosolic and membrane fraction from PTCs
Once confluent cultures were treated according to the .
Immunoblot analysis
When each animal experiment was finished, whole kidneys or manually dissected slices of renal cortex were homogenized in a buffer containing 250 mM sucrose, 10 mM triethanolamine, 1 μg/mL leupeptin, and 0.1 mg/ mL phenylmethylsulfonyl fluoride titrated to pH 7.6.
Coomassie-stained "loading gels" were done to assess the quality of the protein by sharpness of the bands and to adjust protein concentrations before immunoblotting 14) .
For immunoblotting, the proteins were transferred electrophoretically from unstained gels to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). After being blocked with 5% skim milk in PBS-T (80 mM Na 2 HPO 4 , 20 mM NaH 2 PO 4 , 100 mM NaCl, 0.1 percent Tween-20, 
Quantitative polymerase chain reaction (QPCR)
Total RNA was isolated from the rat whole kidneys Specificity was ensured by postrun melting curve analysis.
Primary antibodies
For immunoblot analysis from rat kidneys, we used polyclonal antibodies against AQP1 and AQP2 19) . 
Statistics
Values are presented as means ± SE. Comparisons between cyclophosphamide-treated and control rats were performed by the Mann-Whitney U-test. P values of less than 0.05 were considered statistically significant. mg/kg BW) of cyclophosphamide produced no significant changes in urine output, urine osmolality, plasma sodium and creatinine concentration, and creatinine clearance.
Results
Effects of cyclophosphamide administration on rat kidneys
The levels of AQP1 protein expression estimated in whole kidney homogenates were 100 ± 18%, 136 ± 53%, 244 ± 38%, 614 ± 194%, and 460 ± 46% at 0, 12, 24, 48, and 96 mg/kg BW doses, respectively. Thus, high doses of cyclophosphamide administration produced significant increases in AQP1 protein expression as compared with vehicle-treated controls (P < 0.005 at 48 mg/kg BW; P < 0.05 at 96 mg/kg BW). The expression of AQP2 protein also showed an increasing tendency at high doses of cyclophosphamide but did not reach the statistical significance ( Fig. 1) . however, revealed no significant differences in mRNA levels between treated versus control rats (Fig. 4) : AQP1, 75 ± 11 vs. 100 ± 21%; AQP7, 105 ± 16 vs. 100 ± 13%; AQP2, 81 ± 14 vs. 100 ± 13%; and vasopressin-2 receptor, 96 ± 33 vs. 100 ± 13%.
Effects of 4-HC treatment on rabbit PTCs
In order to examine the effect of an active metabolite of cyclophosphamide on the expression of water channel proteins in primary cultured renal PTCs, we treated rabbit PTCs with 4-HC (0-30 μmol/L) for 24 hours. In immunoblotting using membrane fraction of PTCs, protein expression levels of AQP1 and AQP7 were increased in a dose-dependent manner by 4-HC treatment (Fig. 5 ).
Discussion
The kidney is able to regulate water excretion to maintain water balance. Renal conservation of water occurs partly in association with sodium reabsorption in the proximal tubule and thin limb of Henle's loop and partly as a result of action of vasopressin on the collecting duct. AQP1 and AQP2 are the major water channels to mediate water reabsorption in the proximal nephron and collecting duct, respectively.
Excessive accumulation of water results in dilutional hyponatremia. It usually occurs due to impaired renal excretion of water rather than excessive water intake because the capacity for water excretion normally is so great.
When drugs affect water homeostasis, they can impair the renal diluting capacity in 3 ways 20) . The first possibility is that they can increase vasopressin secretion centrally.
However, plasma vasopressin levels are not elevated in patients following the administration of intravenous cyclophosphamide 21, 22) . In addition, antidiuresis was reported to occur in response to intravenous cyclopho sphamide in an 8 year-old girl with central diabetes insipidus 23) , excluding the possibility of a drug-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH).
The second possibility is reset osmostat, lowering the threshold for vasopressin secretion. This condition is usually associated with a long-term course of hyponatremia such as spinal cord injury, psychiatric problems, and alcoholism 24) , but cyclophosphamide-induced water retention is an acute process. The injection of cyclophosphamide into normally hydrated patients caused antidiuresis beginning in 4 to 12 hours and lasting as long as 20 hours 25) .
The third possibility is that cyclophosphamide may potentiate the action of vasopressin on the kidney. This postulation is very plausible, but has never been verified for decades. Recently, only carbamazepine was reported to increase AQP2 expression 26) . In this study, the protein expression of AQP2 seemed to increase, although statistical significance was not reached. Further studies
will be required to demonstrate the role of AQP2 in cyclophosphamide-induced hyponatremia.
This study was focused to elucidate the role of the AQP1 water channel in cyclophosphamide-induced water retention. We tested whether AQP1 protein may be affected by cyclophosphamide administration in rat kidneys. In addition, primary cultured renal PTCs were treated with 4-HC because the cyclophosphamide-induced antidiuresis was related to the urinary excretion of active alkylating metabolites of the drug 25) .
To avoid the occurrence of hemorrhagic cystitis, we used moderate doses of a single cyclophosphamide administration. In Animal Experiment I, the increase in AQP1 protein expression was remarkable when 48 and 96 mg/kg BW cyclophosphamide were administered (Fig. 1) . However, hyponatremia was not found in these rats ( Table 1 ). Considering that cyclophosphamideinduced hyponatremia usually occurs 4-12 hours after the intravenous administration of the drug, we may have to test an earlier change in plasma sodium level.
The results of Animal Experiment II suggest that the increase in AQP1 protein may persist for more than several days after a single cyclophosphamide administration (Fig.   2 ). Cyclophosphamide-treated rats had a significantly lower plasma sodium concentration. Although weight gain was smaller in these animals, urine sodium excretion was not different between treated and control rats (Table 1 ). Thus we think that the main cause of hyponatremia in these cyclophosphamide-treated rats is water retention rather than hypovolemia.
Consistent with the animal studies, we found that treat ment of primary cultured renal PTCs with an active metabolite of cyclophosphamide (4-HC) increased protein expressions of AQP1 and AQP7 in a dose-dependent manner (Fig. 5) . Previous studies reported that AQP7 was localized selectively at the brush border membranes of proximal straight tubule (segment 3 proximal tubule, S3)
in the rat kidney, suggesting that AQP7 may function as a pathway for transcellular water transport in S3 in concert with more widely expressed AQP1 in proximal tubules 27, 28) . Thus, the proximal nephron should be one of the major target sites where cyclophosphamide-induced water retention occurs.
Despite the notable changes in AQP1 and AQP7 protein, we found no differences in the mRNA levels between cyclophosphamide-treated and control rats (Fig. 4) . It is conceivable that other mechanisms such as decreased protein degradation than transcriptional regulation may exert to affect the AQP1 protein level. Further studies 
